WO2012023510A1 - Implant biologique - Google Patents

Implant biologique Download PDF

Info

Publication number
WO2012023510A1
WO2012023510A1 PCT/JP2011/068431 JP2011068431W WO2012023510A1 WO 2012023510 A1 WO2012023510 A1 WO 2012023510A1 JP 2011068431 W JP2011068431 W JP 2011068431W WO 2012023510 A1 WO2012023510 A1 WO 2012023510A1
Authority
WO
WIPO (PCT)
Prior art keywords
test
weight
bone
test piece
silver
Prior art date
Application number
PCT/JP2011/068431
Other languages
English (en)
Japanese (ja)
Inventor
正明 馬渡
岩男 野田
Original Assignee
国立大学法人佐賀大学
日本メディカルマテリアル株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人佐賀大学, 日本メディカルマテリアル株式会社 filed Critical 国立大学法人佐賀大学
Priority to US13/817,168 priority Critical patent/US20130138223A1/en
Priority to EP11818152.8A priority patent/EP2606916A4/fr
Publication of WO2012023510A1 publication Critical patent/WO2012023510A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/28—Bones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/30—Inorganic materials
    • A61L27/32—Phosphorus-containing materials, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • A61L2300/104—Silver, e.g. silver sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/12—Materials or treatment for tissue regeneration for dental implants or prostheses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/24—Materials or treatment for tissue regeneration for joint reconstruction

Definitions

  • the present invention relates to a biological implant having antibacterial properties.
  • bioimplants for the treatment of both bone injuries / diseases is constantly expanding with an increasing active and elderly population.
  • bone substitutes for bone crushing and bone removal or the use of supports for weakened bones, artificial bone substitutes form a strong joint or bone with the native bone, resulting in structural integrity. You need to ensure. Bone can grow into adjacent structures, especially if the adjacent structure is porous and comparable to bone. However, bone must not only grow into a porous structure, but also bond to allow strong adhesion between the native bone grown in the porous structure and the bioimplant.
  • Patent Document 1 a method of coating an HA layer having a high crystallinity and a large specific surface area, suitable for impregnation with antibiotics, by precipitating HA on the surface of a biological implant and drying it, antibiotics on the coating layer
  • Patent Document 1 A therapeutic agent-impregnated biological implant that impregnates the like has been proposed (Patent Document 1).
  • this method is suitable for impregnation with antibiotics, but the pore size and porosity of the film are uniform, so it is difficult to release the drug at a desired rate, and the drug elutes at a constant rate. There is a problem that it is easy to do.
  • Patent Document 2 proposes a method of adjusting the disappearance rate of HA by adjusting the crystallinity of the coating layer made of a calcium phosphate material, thereby adjusting the release rate of the antibacterial agent or antibacterial agent ( Patent Document 2).
  • antibacterial agents While antibacterial agents have antibacterial properties, they have a problem that they act on cell enzymes and cell membranes and are toxic in a concentration-dependent manner. Therefore, there is a need for a biological implant that is not only antibacterial but has high in-vivo safety that does not exhibit toxicity to biological tissues or organs.
  • an object of the present invention is to provide a biological implant having excellent antibacterial properties and high in-vivo safety.
  • the living body implant of the present invention has a sprayed coating made of a calcium phosphate-based material formed on at least a part of a base made of metal, ceramics, or plastic, and the silver concentration in the sprayed coating is 0. 0.02% to 3.00% by weight.
  • the calcium phosphate material is preferably one or a mixture of two or more selected from the group consisting of hydroxyapatite, ⁇ -tricalcium phosphate, ⁇ -tricalcium phosphate and quaternary calcium phosphate.
  • the thickness of the sprayed coating is preferably 5 to 100 ⁇ m.
  • an infection healing promotion effect can be obtained by a bactericidal effect due to high antibacterial activity. Moreover, since it is highly safe in the living body, it can be used safely even for patients with low resistance such as a recently developed compromised host (susceptible host).
  • a sprayed coating made of a calcium phosphate-based material is formed on at least a part of a substrate made of metal, ceramics or plastic, and the silver concentration in the sprayed coating is 0.02 wt% to 3. It is characterized by being 00% by weight.
  • an artificial bone or internal fixture used for the treatment of diseases or trauma or an artificial joint or tooth used to reconstruct a lost joint function It includes metal, ceramic or plastic implants such as artificial tooth roots used.
  • metal, ceramics, or plastic can be used for the base of the biological implant.
  • metal stainless steel alloy, cobalt-chromium alloy, titanium, titanium alloy, alumina, zirconia, and the like can be used, but titanium or titanium alloy is preferable.
  • titanium alloy an alloy to which at least one of aluminum, tin, zirconium, molybdenum, nickel, palladium, tantalum, niobium, vanadium, platinum and the like are added can be used.
  • a Ti-6Al-4V alloy is preferable.
  • ceramics for example, alumina, zirconia, alumina / zirconia composite ceramics, or the like can be used.
  • plastic for example, polyethylene, fluorine resin, epoxy resin, PEEK resin, bakelite and the like can be used.
  • the calcium phosphate material one or a mixture of two or more selected from the group consisting of hydroxyapatite, ⁇ -tricalcium phosphate, ⁇ -tricalcium phosphate and quaternary calcium phosphate can be used. Preferably, it is hydroxyapatite.
  • thermal spraying method used for forming a thermal spray coating made of a calcium phosphate material
  • flame spraying high-speed flame spraying, plasma spraying, and cold spraying.
  • a coating is formed by spraying a sprayed material on a surface of a base material in a molten or nearly melted state using a gas flame of oxygen and a combustible gas as a heat source.
  • the spraying temperature is about 2700 ° C. and the spraying speed is Mach 0.6.
  • thermal spraying can be performed at a spraying distance of 60 to 100 mm by introducing thermal spraying powder with 100 psi dry air into a gas flame torch of oxygen gas 50 psi and acetylene gas 43 psi.
  • the thickness of the sprayed coating is 5 to 100 ⁇ m, preferably 20 to 40 ⁇ m. If the thickness is less than 5 ⁇ m (the entire sprayed portion cannot be covered, and if it is thicker than 100 ⁇ m, the adhesion strength of the coating is reduced due to residual stress during spraying.
  • the silver concentration in the thermal spray coating can be adjusted by changing the amount of the silver raw material to be blended with the calcium phosphate material as the thermal spray material.
  • the silver concentration in the sprayed coating is 0.02 wt% to 3.00 wt%, preferably 0.02 wt% to 2.50 wt%, more preferably 0.02 wt% to 2.00 wt%, It is preferably 0.02% by weight to 1.11% by weight. This is because if it is less than 0.02% by weight, the antibacterial property is not sufficient. Moreover, it is because it will show toxicity to a biological tissue and organ when it exceeds 3.00 weight%.
  • argillosis a disease that causes the skin tone of the whole body to become gray
  • white blood cells a decrease in white blood cells
  • damage to the liver and kidneys it has been found that when the silver concentration is more than 3.00% by weight, cell deformation and formation of new bone are inhibited.
  • an artificial joint having a stem and a neck portion formed at the upper end of the stem and fixing a head ball, and at least a part of the surface of the neck portion is calcium phosphate-based.
  • examples thereof include an artificial joint in which a sprayed coating made of a material is formed, and the silver concentration in the sprayed coating is 0.02 wt% to 3.00 wt%.
  • the artificial joint is preferably made of titanium or a titanium alloy.
  • Example 1 (Test piece preparation) A thermal spray coating having a thickness of about 40 ⁇ m was formed on one surface of a 50 mm ⁇ 50 mm ⁇ 2 mm pure titanium plate by spraying hydroxyapatite with a predetermined amount of silver oxide added thereto by flame spraying. By changing the amount of silver oxide added, test pieces having silver concentrations in the sprayed coating of 0.02, 0.07, 0.16, 0.21, and 0.42% by weight were produced.
  • Flame spraying was performed by introducing spray powder with dry air of 100 psi into a gas flame torch of oxygen gas 50 psi and acetylene gas 43 psi, and spraying at a spray distance of 60 to 100 mm.
  • the test piece was sufficiently dried at 100 ° C., weighed and then dissolved in a nitric acid solution (5 mL of nitric acid + 50 mL of pure water). The silver concentration in this solution was quantitatively analyzed by ICP emission spectroscopy, and the silver concentration in the film was determined. Next, the test piece after the film was dissolved and removed was sufficiently dried, weighed again, and the film weight was determined from the weight difference from before the film was dissolved. The silver concentration (% by weight) in the film was calculated by dividing the amount of silver in the film by the weight of the film.
  • Antimicrobial performance test In accordance with JIS Z 2801 “antibacterial processed product-antibacterial test method / antibacterial effect”, antibacterial activity against Escherichia coli and MRSA (methicillin-resistant Staphylococcus aureus) was evaluated to determine an antibacterial activity value. However, assuming that this antibacterial member is used in vivo, bovine serum was used instead of 1/500 normal broth medium for the purpose of simulating the biological environment. The culture temperature was also changed from 35 ° C to 37 ° C. Incubation was performed in the dark for 24 hours.
  • the antibacterial activity value (R) is a value indicating the difference in the logarithmic value of the number of viable bacteria after inoculating and culturing bacteria in the antibacterial processed product and the unprocessed product, and is defined by the following equation.
  • Antibacterial activity value log [(average value of viable cell count after 24 hours of unprocessed test piece) / (average value of viable cell count after 24 hour of antibacterial processed test piece)]
  • an antibacterial activity value R of 7 indicates that the number of bacteria has become 1/10 7 before the test. According to the JIS standard, when the antibacterial activity value is 2 or more, it is determined that the antibacterial activity is effective.
  • FIG. 1 is a graph showing the relationship between the antibacterial activity value R and the silver concentration (% by weight) in the thermal spray coating. When the silver concentration was 0.02% by weight or more, the antibacterial activity value R was 2 or more, indicating high antibacterial activity against both E. coli and MRSA.
  • Example 2 (Test piece preparation) A test piece in which the silver concentration in the sprayed coating is 0.21, 1.11, 3.48, and 13.03 wt% by using the same method as in Example 1 and changing the addition amount of silver oxide. Was made. For control, a test piece sprayed with hydroxyapatite to which no silver oxide was added was prepared. The test piece has a diameter of 14 mm and a thickness of 1 mm.
  • Cell adhesion test The cell adhesion test was performed according to the following procedure. A mouse-derived osteoblast progenitor cell line MC3T3-E1 was pre-cultured and then seeded on a specimen immersed in ⁇ -MEM + 10% FBS. After culturing at 37 ° C. for 5 h with 5% CO 2 , the cytoskeleton and nucleus were fluorescently stained, and the number of attached cells was measured and the morphology was observed.
  • Table 1 shows the cell diameter ratio (%) after the test at each silver concentration.
  • the cell ratio after the test is a ratio with respect to the cell diameter when the silver concentration is zero, and is obtained by taking a photograph and measuring the diameters of many cells in the photograph and averaging them.
  • the silver concentration is 3.48% by weight
  • the cell diameter is as small as 81% and 13.03% by weight, 74%, indicating that silver exhibits toxicity to cells.
  • Example 3 (Animal experiment 1: Bacterial infection test) A bacterial infection test was performed on a test piece having a silver concentration of 0.21% by weight prepared in the same manner as in Example 1. For control, a test piece sprayed with hydroxyapatite to which no silver oxide was added was prepared. The test piece has a diameter of 8 mm and a thickness of 1 mm. The bacterial infection test was performed according to the following procedure. The above-mentioned test piece was implanted subcutaneously in the back of male SD rats (weight: 300-350 g) under Nembutal abdominal anesthesia, and methicillin-resistant Staphylococcus aureus (biofilm-forming ability separated from clinical material) MRSA) was inoculated with 1.2 ⁇ 10 6 CFU. After feeding for 72 hours on a normal feed, a test piece was collected, ultrasonically washed (5 minutes), and the number of bacteria contained in the washing solution was evaluated by a plate culture method.
  • MRSA methicillin-resistant Staphylococcus au
  • the average MRSA adhesion number (CFU) per specimen was 1.5 ⁇ 10 5 in the control group and 1.1 ⁇ 10 4 (P ⁇ 0.001) in the 0.21 wt% test group. A decrease in the number of bacteria was observed for the test piece of this example, and it was confirmed that the antibacterial properties of the test piece of this example also acted effectively in vivo.
  • Example 4 (Animal experiment 2: bone implant test) An intraosseous implant test was performed on a test piece having a silver concentration of 0.21 and 13.03 wt% produced by the same method as in Example 1. For control, a test piece sprayed with hydroxyapatite to which no silver oxide was added was prepared. The test piece has a diameter of 1 mm and a length of 20 mm.
  • the bone formation rate was 73.5% in the control group, 74.8% in the test group of 0.21% by weight, and the same value in the test group of the Kotrol group and 0.21% by weight.
  • the 03 wt% test group showed a low value of 31.7%. This is considered to be a result of inhibition of new bone formation due to toxicity to bone cells by high concentration of silver.
  • Example 5 The test piece having a silver concentration of 0.21% by weight prepared in Example 2 was subjected to a cytotoxicity test based on ISO10993-5. Specifically, the colony formation test by the extraction method and the direct method was performed. The extraction method is for evaluating the toxicity due to the extract (eluate) from the test piece, and the direct method is a test for directly evaluating the toxicity of the surface of the test piece. As a control, a test piece sprayed with hydroxyapatite to which no silver oxide was added was used. The test method is as follows.
  • Example 5 M05 medium was added at a rate of 1 mL with respect to the surface area of 6 cm 2 of the test piece, and extracted at 37 ° C. for 24 hours. V79 cells were seeded in a petri dish, and the extract was added in a dilution series. After culturing at 37 ° C. for 6 days, fixation and Giemsa staining were performed, the number of colonies was counted to determine the colony formation rate, and IC50 (50% lethality) was calculated.
  • test piece was closely attached to the bottom of the petri dish and seeded with V79 cells.
  • the cells were cultured in MEM10 medium at 37 ° C. for 6 days, fixed and then stained with Giemsa. The number of colonies was counted to determine the colony formation rate, and compared with negative and positive subjects.
  • the IC50 was 100% or more in both the control group and the 0.21% by weight test group, and toxicity due to this material was not observed.
  • the colony formation rate was 72.4% in the control group and 71.4% in the test group of 0.21% by weight, and there was no toxicity considered to be attributable to silver. .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La présente invention concerne un implant biologique qui a d'excellentes propriétés antimicrobiennes et est très sûr dans des corps vivants. Pour cet implant biologique, un revêtement par pulvérisation comprenant un matériau de phosphate de calcium est formé sur au moins une partie d'un substrat de métal, de céramique ou de plastique et la concentration d'argent dans le revêtement par pulvérisation est de 0,02 % en poids à 3,00 % en poids.
PCT/JP2011/068431 2010-08-19 2011-08-12 Implant biologique WO2012023510A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/817,168 US20130138223A1 (en) 2010-08-19 2011-08-12 Bioimplant
EP11818152.8A EP2606916A4 (fr) 2010-08-19 2011-08-12 Implant biologique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010-184230 2010-08-19
JP2010184230A JP2012040194A (ja) 2010-08-19 2010-08-19 生体インプラント

Publications (1)

Publication Number Publication Date
WO2012023510A1 true WO2012023510A1 (fr) 2012-02-23

Family

ID=45605164

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/068431 WO2012023510A1 (fr) 2010-08-19 2011-08-12 Implant biologique

Country Status (4)

Country Link
US (1) US20130138223A1 (fr)
EP (1) EP2606916A4 (fr)
JP (1) JP2012040194A (fr)
WO (1) WO2012023510A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013114947A1 (fr) * 2012-02-03 2013-08-08 国立大学法人佐賀大学 Bio-implant
US10814039B2 (en) 2012-02-03 2020-10-27 Kyocera Corporation Bioimplant with antibacterial coating and method of making same
US11998659B2 (en) 2006-09-08 2024-06-04 Kyocera Corporation Bioimplant with evanescent coating film

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015016231A (ja) * 2013-07-12 2015-01-29 京セラメディカル株式会社 生体インプラント
JP6592823B2 (ja) * 2015-06-30 2019-10-23 京セラ株式会社 生体インプラント
CN107469155B (zh) * 2017-08-10 2018-06-22 中南大学湘雅医院 一种缓释抗菌复合植骨材料及其制备方法
JP7304213B2 (ja) * 2019-06-12 2023-07-06 日本特殊陶業株式会社 生体適合部材
EP4098228A4 (fr) * 2020-01-31 2024-03-13 Kyocera Corporation Implant rachidien et procédé de fabrication d'implant rachidien
US20230147429A1 (en) * 2020-03-30 2023-05-11 Saga University Artificial joint stem and method for manufacturing artificial joint stem
AU2021260003B2 (en) * 2020-04-22 2024-04-18 Kyocera Corporation Shell for artificial joint and method for producing same
AU2020450413A1 (en) * 2020-05-29 2023-01-19 Kyocera Corporation Stem for artificial joint

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005506879A (ja) 2001-10-24 2005-03-10 ハウメディカ・オステオニクス・コーポレイション 抗生リン酸カルシウムコーティング
JP2008073098A (ja) 2006-09-19 2008-04-03 Saga Univ 生体インプラント
JP2010065304A (ja) * 2008-09-12 2010-03-25 Saga Univ 抗菌製品及びその製造方法並びに生体インプラント

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007144667A2 (fr) * 2006-06-12 2007-12-21 Accentus Plc Implants métalliques
WO2008029612A1 (fr) * 2006-09-08 2008-03-13 Japan Medical Materials Corporation Bio-implant
DE102008057026A1 (de) * 2007-11-12 2009-05-28 Medicoat Ag Implantat und Verfahren zur Beschichtung eines Implantats

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005506879A (ja) 2001-10-24 2005-03-10 ハウメディカ・オステオニクス・コーポレイション 抗生リン酸カルシウムコーティング
JP2008073098A (ja) 2006-09-19 2008-04-03 Saga Univ 生体インプラント
JP2010065304A (ja) * 2008-09-12 2010-03-25 Saga Univ 抗菌製品及びその製造方法並びに生体インプラント

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANDO ET AL.: "Development of antibacterial biomaterials", ORTHOPAEDIC SURGERY AND TRAUMATOLOGY, vol. 53, no. 5, 30 April 2010 (2010-04-30), pages 467 - 475 *
NODA ET AL.: "Development of Novel Thermal Sprayed Antibacterial Coatingand Evaluation of Release Properties of Silver Ions", J BIOMED MATER RES PART B: APPL BIOMATER, vol. 89B, 2008, pages 456 - 465, XP055083008 *
See also references of EP2606916A4
SHIMAZAKI ET AL.: "In Vivo Antibacterial and Silver-Releasing Properties of NovelThermal Sprayed Silver-Containing Hydroxyapatite Coating", J BIOMED MATER RES PART B: APPL BIOMATER, vol. 92B, 2009, pages 386 - 389, XP055083007 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11998659B2 (en) 2006-09-08 2024-06-04 Kyocera Corporation Bioimplant with evanescent coating film
WO2013114947A1 (fr) * 2012-02-03 2013-08-08 国立大学法人佐賀大学 Bio-implant
JPWO2013114947A1 (ja) * 2012-02-03 2015-05-11 国立大学法人佐賀大学 生体インプラント
EP2810665A4 (fr) * 2012-02-03 2015-09-09 Univ Saga Bio-implant
JP2017127744A (ja) * 2012-02-03 2017-07-27 国立大学法人佐賀大学 生体インプラント
US10814039B2 (en) 2012-02-03 2020-10-27 Kyocera Corporation Bioimplant with antibacterial coating and method of making same
US11577006B2 (en) 2012-02-03 2023-02-14 Kyocera Corporation Bioimplant

Also Published As

Publication number Publication date
EP2606916A1 (fr) 2013-06-26
US20130138223A1 (en) 2013-05-30
JP2012040194A (ja) 2012-03-01
EP2606916A4 (fr) 2014-01-08

Similar Documents

Publication Publication Date Title
WO2012023510A1 (fr) Implant biologique
Gao et al. Biofunctional magnesium coated Ti6Al4V scaffold enhances osteogenesis and angiogenesis in vitro and in vivo for orthopedic application
JP6289708B2 (ja) 生体インプラント
US11577006B2 (en) Bioimplant
US10004604B2 (en) Bioimplant for artifical joint with evanescent coating film
Shimabukuro et al. Investigation of realizing both antibacterial property and osteogenic cell compatibility on titanium surface by simple electrochemical treatment
CN101511399B (zh) 生物植入物
Vogely et al. Effects of hydroxyapatite coating on Ti‐6 Al‐4V implant‐site infection in a rabbit tibial model
Niu et al. Development of a bioactive composite of nano fluorapatite and poly (butylene succinate) for bone tissue regeneration
US10610614B2 (en) Bioimplant with evanescent coating film
EP3509650B1 (fr) Dispositifs médicaux implantables comportant une couche de revêtement ayant des propriétés antimicrobiennes à base d'hydroxyapatite nanostructurée
US20220241461A1 (en) Bioimplant with evanescent coating film
Yu et al. Synergistic effect of a biodegradable Mg–Zn alloy on osteogenic activity and anti-biofilm ability: an in vitro and in vivo study
KR20160023720A (ko) 콜라겐-vi을 포함하는 의료 기구
RU2632761C1 (ru) Ортопедический имплантат из титана и нержавеющей стали с антиадгезивным антибактериальным покрытием
Graziani et al. Ionized jet deposition of silver nanostructured coatings: Assessment of chemico-physical and biological behavior for application in orthopedics
RU2632702C1 (ru) Антиадгезивное антибактериальное покрытие для ортопедических имплантатов из титана и нержавеющей стали
Li et al. Preparation and properties of a 3D printed nHA/PLA bone tissue engineering scaffold loaded with a β-CD–CHX combined dECM hydrogel
JP2009018086A (ja) 繊維芽細胞成長因子徐放性生体材料
RU2816023C1 (ru) Антибактериальное покрытие на ортопедический имплантат из титана и его сплавов и способ его получения (варианты)
Sutha et al. Fabrication of duplex-layer coating on metallic implants: Advanced surface modification of metallic implants for orthopedic applications
Ibrahim et al. Mechanical evaluation of nano hydroxyapatite, chitosan and collagen composite coating compared with nano hydroxyapatite coating on commercially pure titanium dental implant
RU2472532C1 (ru) Остеоинтеграционное покрытие на ортопедические и стоматологические титановые имплантаты
Sreeranjini BIOMATERIALS AND ITS APPLICATIONS IN REGENERATIVE MEDICINE
Gouveia Development Of Hybrid Coating Materials To Improve The Success Of Titanium Implants

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11818152

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2011818152

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13817168

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE